Theralase Technologies Inc. V.TLT

New Press Release - Theralase(R) Release's 1Q2024 Financial Statements

TORONTO, ON / ACCESSWIRE / May 30, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the...read article.

[Lesalpes29]

Time to secure enough $ to continue. We really need a partner to cross the finish line in senerity and security. 

[Oilminerdeluxe]

The Company submitted a pre-Break Through Designation (" BTD ") submission to the FDA in July 2023 and based on the FDA's feedback, the Company is currently working with the Clinical Study Sites (" CSSs "), a biostatistics organization and a regulatory organization to update the pre-BTD with clinical data clarifications identified by the FDA. The Company

[StevenBirch]

Duration of response up to 3 years and 5 more patients treated, not all is lost.

[anabelsi]

Yes, this gives me some hope... I am looking forward to the zoom call next week, I hope that it will be more informative than the last one though

[Lesalpes29]

Yes Steven. Happy with those numbers. Quite positive and my glass is still half full. Somebody is paid to find money for the next at least 1.5 year. Let find it.

[Donein25]

But no mention of 2 year data...which seems to be the new  benchmark for FDA. Also, it looks to me like CR% are decreasing accross the board. Can someone confirm that impression? Also, last October they announced Optimization to include additional treatment for recurrence. Why has there been no data on these retreatments? One would think re-reatment would be driving CR % higher.

[enriquesuave]

Overall the data is very strong IMO.  We are probably going to see in the end 35-40% CR at 45 days.  If we can maintain 25-30% CR at 24 months, we will be looking way above the competition.  Only 33 patients got a 2nd treatment ( maintenance treatment) out of 62.  I don't know why not all 62 patients received a 2nd treatment?  It seems no one yet received a 3rd

[enriquesuave]

The primary benefits of the Theralase® technology versus competitive technologies are the: urologist-led treatment, single out-patient treatment, high efficacy rates (patients achieve a CR in 58% of the cases after only one Study Procedure), high duration of response (up to 3 years) and high safety margin (no SAEs directly associated with the Study Drug or Study Device); therefore, the

[Infinity]

Nothing much that is new in this update.  The waiting continues.  The patient enrollment is more or less stagnant.  5 or 6 patients added in one year?  No explanation given for this lack of patient interest or any mention of efforts being made, like increasing the CSS overseas in Europe, Australia or Asia for that matter.  This is frequently done by other Pharma companies

[blackjack0]

This is an increase of five treatments since the last update so I think their enrolment is picking up again .as far as treating patients in places other than the USA and Canada that involves a lot of cash, something big pharma have in abundance but Theralase does not. The data seems to be continuing to show improvement but I await the posters that have expertise in breaking down the numbers 

[plantrader]

Wondering about the below taken from the statement. Do we know how many of these carry foward patients there are? Have they ever told us? I could have missed that, I'm sure. Is it possible that the FDA doesn't consider carry-forward statistics valid because they're based on the past and not confirmed in the present, and therefore the data isn't as good as we think it is? For